Morgan Stanley continues to support
Haleon plc (HLN) with a Buy rating and a price target of $10.95. However,
Berenberg lowers the target price to $13.41 due to slower growth expectations. Haleon has executed several actions to enhance shareholder value including a series of share buybacks, enhancing its capital structure. Despite this, Haleon's stocks have seen a decrease in prices, plunging by 2.08% within two days and have hit a historic low since April 2025. Further insider share transactions and partnership with the
Indian Dental Association to host the
DENTAL 20 International Symposium were also announced. The company has revised its organic revenue growth outlook due to North American weakness causing a slight dip in the stock. Interestingly, the company's aggressive share buyback actions coupled with recent executive share acquisitions, CEO change, and new partnerships like the one with
Brightseed have caught investors' attention. The company appears to be a favorable low-priced pharma stock amidst market sell-offs. Haleon also announced updates on total voting rights and capital, giving investors a glimpse into the company’s executive share vesting and regulatory compliance scenario. The company's final tranche of shares was sold to Pfizer for $3.2 billion, concluding Pfizer's stake in the healthcare giant.
Haleon Stocks News Analytics from Wed, 15 Jan 2025 08:00:00 GMT to Fri, 15 Aug 2025 22:46:25 GMT -
Rating -3
- Innovation 6
- Information 5
- Rumor -2
